Burzynski Research Institute (BZYR) Total Current Liabilities (2011 - 2021)
Burzynski Research Institute (BZYR) posted Total Current Liabilities of $46799.0 for Q1 2021, down 72.86% sequentially from $172440.0 in Q1 2020, and down 72.86% YoY from $172440.0 in Q1 2020.
Burzynski Research Institute (BZYR) Total Current Liabilities (2011 - 2021) Analysis & Trends
Burzynski Research Institute has reported Total Current Liabilities for 11 years, with the latest figure at $46799.0 in Q1 2021.
- Quarterly Total Current Liabilities fell 72.86% year-over-year to $46799.0 in Q1 2021, while the trailing twelve-month figure through Feb 2021 was $46799.0 (down 72.86% YoY) and the FY2021 annual result came in at $46799.0, down 72.86% from the prior year.
- Total Current Liabilities declined to $46799.0 in Q1 2021 per BZYR's latest filing, from $172440.0 in the prior quarter.
- Over five years, Total Current Liabilities peaked at $208820.0 in Q1 2019 and troughed at $43732.0 in Q1 2017.
- A 5-year average of $121684.0 and a median of $136629.0 in 2018 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2018 and 2021: Total Current Liabilities soared 212.42% in 2018, then tumbled 72.86% in 2021.
- Over 5 years, Total Current Liabilities stood at $43732.0 in 2017, then jumped by 212.42% to $136629.0 in 2018, then soared by 52.84% to $208820.0 in 2019, then slipped by 17.42% to $172440.0 in 2020, then sank by 72.86% to $46799.0 in 2021.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $46799.0, $172440.0, and $208820.0 for Q1 2021, Q1 2020, and Q1 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 630.93 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2021 | 46,799.00 |
| Feb 29, 2020 | 172,440.00 |
| Feb 28, 2019 | 208,820.00 |
| Feb 28, 2018 | 136,629.00 |
| Feb 28, 2017 | 43,732.00 |
| Feb 29, 2016 | 105,005.00 |
| Feb 28, 2015 | 141,991.00 |
| Feb 28, 2014 | 152,903.00 |
| Feb 28, 2013 | 88,590.00 |
| Feb 29, 2012 | 61,964.00 |
| Feb 28, 2011 | 72,851.00 |